Redhill Biopharma Net Worth
Redhill Biopharma Net Worth Breakdown | RDHL |
Redhill Biopharma Net Worth Analysis
Redhill Biopharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Redhill Biopharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Redhill Biopharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Redhill Biopharma's net worth analysis. One common approach is to calculate Redhill Biopharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Redhill Biopharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Redhill Biopharma's net worth. This approach calculates the present value of Redhill Biopharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Redhill Biopharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Redhill Biopharma's net worth. This involves comparing Redhill Biopharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Redhill Biopharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Redhill Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Redhill Biopharma's net worth research are outlined below:
| Redhill Biopharma generated a negative expected return over the last 90 days | |
| Redhill Biopharma has high historical volatility and very poor performance | |
| Redhill Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Redhill Biopharma currently holds 1.17 M in liabilities with Debt to Equity (D/E) ratio of 9.89, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Redhill Biopharma has a current ratio of 0.96, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Redhill Biopharma's use of debt, we should always consider it together with its cash and equity. | |
| Redhill Biopharma currently holds about 28.86 M in cash with (35.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55. | |
| Redhill Biopharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from insidermonkey.com: Absci Corporation AI in Biopharma Discovery |
Redhill Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Redhill Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Redhill Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Redhill Biopharma Target Price Consensus
Redhill target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Redhill Biopharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Strong Buy |
Most Redhill analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Redhill stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Redhill Biopharma, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationRedhill Biopharma Target Price Projection
Redhill Biopharma's current and average target prices are 6.33 and 40.00, respectively. The current price of Redhill Biopharma is the price at which Redhill Biopharma is currently trading. On the other hand, Redhill Biopharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Redhill Biopharma Market Quote on 21st of January 2025
Target Price
Analyst Consensus On Redhill Biopharma Target Price
Know Redhill Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Redhill Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Redhill Biopharma backward and forwards among themselves. Redhill Biopharma's institutional investor refers to the entity that pools money to purchase Redhill Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jane Street Group Llc | 2024-09-30 | 0.0 | Sabby Management Llc | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-09-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Aspire Private Capital, Llc | 2024-06-30 | 0.0 | Jpmorgan Chase & Co | 2024-09-30 | 0.0 | F.l.putnam Investment Management | 2024-09-30 | 0.0 | Virtu Financial Llc | 2024-09-30 | 0.0 | Two Sigma Securities, Llc | 2024-09-30 | 0.0 | Federation Des Caisses Desjardins Du Quebec | 2024-09-30 | 4 K | Rhumbline Advisers | 2024-09-30 | 979 |
Follow Redhill Biopharma's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.22 M.Market Cap |
|
Project Redhill Biopharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 1.23 | 1.29 | |
| Return On Capital Employed | 2.99 | 3.14 | |
| Return On Assets | 0.93 | 0.98 | |
| Return On Equity | 10.40 | 10.92 |
When accessing Redhill Biopharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Redhill Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Redhill Biopharma's profitability and make more informed investment decisions.
Evaluate Redhill Biopharma's management efficiency
Redhill Biopharma has return on total asset (ROA) of (0.4488) % which means that it has lost $0.4488 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.0861) %, meaning that it created substantial loss on money invested by shareholders. Redhill Biopharma's management efficiency ratios could be used to measure how well Redhill Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to 1.29 this year. Return On Capital Employed is expected to rise to 3.14 this year. At this time, Redhill Biopharma's Other Assets are quite stable compared to the past year. Return On Tangible Assets is expected to rise to 1.29 this year, although the value of Other Current Assets will most likely fall to about 2.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.37 | 0.35 | |
| Tangible Book Value Per Share | (0.62) | (0.59) | |
| Enterprise Value Over EBITDA | 7.94 | 8.34 | |
| Price Book Value Ratio | 102.85 | 102.13 | |
| Enterprise Value Multiple | 7.94 | 8.34 | |
| Price Fair Value | 102.85 | 102.13 | |
| Enterprise Value | 266.9 M | 303.6 M |
Examining the leadership quality of Redhill Biopharma offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Enterprise Value Revenue 0.1346 | Revenue | Quarterly Revenue Growth (0.28) | Revenue Per Share | Return On Equity |
Redhill Biopharma Corporate Filings
6K | 10th of December 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 9th of August 2024 Other Reports | ViewVerify | |
| 7th of August 2024 Other Reports | ViewVerify |
Redhill Biopharma Earnings per Share Projection vs Actual
Redhill Biopharma Corporate Management
| Reza Fathi | Senior Development | Profile | |
| Kristin Comer | G VP | Profile | |
| Valerie Graceffa | VP Sales | Profile | |
| Razi Ingber | Chief Officer | Profile | |
| Rob Jackson | VP Marketing | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (302.63) | Revenue Per Share | Quarterly Revenue Growth (0.28) | Return On Assets | Return On Equity |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.